Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Research facility
Location:
Napoli,
Italy (IT)
ISNI: 0000000417608805
ROR: https://ror.org/0506y2b23
Show on Map:
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019)
Van Herpen CM, Agarwala SS, Hauschild A, Berking C, Thaddeus Beck J, Schadendorf D, Jansen R, et al.
Journal article
MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018)
Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al.
Conference contribution
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018)
Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al.
Conference contribution
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018)
Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, et al.
Journal article
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016)
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, et al.
Journal article